Fig. 4: Response to adalimumab correlates with the frequency of IL17A⁺ T cells and CD274 expression in DC.

Immunophenotyping of PBMCs of psoriasis patients at w0 and at w1 and w12 after starting adalimumab therapy. a Frequency of IL10+ and IL17A+ CD4, CD8 T cells and Tregs at different time points, each line represents one patient (n = 19) (p Tc17 W0vsW1 = 0.0014, W0vsW12 = 3.8 × 10⁻⁶; IL17A Tregs W0vsW1 = 0.045, W0vsW12 = 0.018). b Correlation analyses between the frequency of IL17A+ or IL10+ cells within CD4, CD8 or Tregs and residual disease at w12 (n = 26–28). c Representative flow cytometry colour-plots (left) and violin plots graphs of the frequency of cytokine-producing cells in adalimumab PASI75 responders (R, blue, n week 0 = 18, n week 12 = 15) and non-responders (NR, red, n week 0 = 8, n week 12 = 13) (p Th17 w0 = 0.0051, Tc17 w0 = 0.047, IL17A Tregs w0 = 0.011, Tc17 w12 = 0.0037). d Correlation analyses between the expression of CD274 at w1 and residual disease at w12 in cDC1 and cDC2 (n = 27). e Representative histograms overlay graphs (left) and violin plots graphs (right) of CD274 expression in DC of PASI75 adalimumab responders (blue, n = 17) and non-responders (red, n = 10) *p = 0.045, **p = 0.0058. Kruskal–Wallis with Dunn’s multiple comparisons post-test (a), Mann–Whitney U test (c) or unpaired t test (e). All tests are two-sided. Source data are provided as a Source Data file.